Teva Pharmaceutical Industries Ltd (TEVA) stock
TEVANYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 7/30128% above fair value
$42.62+0.05 (+0.12%)
Close on Nov 17, 2026Market cap $49.66BP/E 71.0Yield –
Teva Pharmaceutical Industries gross profit
Gross profit is revenue minus the direct cost of the goods and services sold.
Teva Pharmaceutical Industries's gross profit for the twelve months ending Jun 30, 2026 was $9.09B, up 10.1% year over year. For fiscal 2025 it was $8.94B, up 10.8% from the year before. Over ten years it grew -2.4% a year on average. The highest annual figure on record is $11.65B in fiscal 2016.
Annual gross profit
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $8.94B | +10.8% |
| FY2024 | Dec 31, 2024 | $8.06B | +5.5% |
| FY2023 | Dec 31, 2023 | $7.65B | +9.6% |
| FY2022 | Dec 31, 2022 | $6.97B | -8.2% |
| FY2021 | Dec 31, 2021 | $7.59B | -1.7% |
| FY2020 | Dec 31, 2020 | $7.73B | +2.5% |
| FY2019 | Dec 31, 2019 | $7.54B | -9.1% |
| FY2018 | Dec 31, 2018 | $8.30B | -21.8% |
| FY2017 | Dec 31, 2017 | $10.62B | -8.9% |
| FY2016 | Dec 31, 2016 | $11.65B | +2.6% |
| FY2015 | Dec 31, 2015 | $11.36B | +2.7% |
| FY2014 | Dec 31, 2014 | $11.06B | +3.3% |
| FY2013 | Dec 31, 2013 | $10.71B | +0.5% |
| FY2012 | Dec 31, 2012 | $10.65B | +11.9% |
| FY2011 | Dec 31, 2011 | $9.52B | +5.0% |
| FY2010 | Dec 31, 2010 | $9.07B | +23.0% |
| FY2009 | Dec 31, 2009 | $7.37B | +23.4% |
| FY2008 | Dec 31, 2008 | $5.97B | +22.4% |
| FY2007 | Dec 31, 2007 | $4.88B | – |
Quarterly gross profit
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $2.15B | +2.4% |
| Q1 FY2026 | Mar 31, 2026 | $1.97B | +5.1% |
| Q4 FY2025 | Dec 31, 2025 | $2.66B | +25.2% |
| Q3 FY2025 | Sep 30, 2025 | $2.30B | +7.3% |
| Q2 FY2025 | Jun 30, 2025 | $2.10B | +3.9% |
| Q1 FY2025 | Mar 31, 2025 | $1.88B | +6.0% |
| Q4 FY2024 | Dec 31, 2024 | $2.12B | -12.2% |
| Q3 FY2024 | Sep 30, 2024 | $2.15B | +16.0% |
| Q2 FY2024 | Jun 30, 2024 | $2.02B | +12.7% |
| Q1 FY2024 | Mar 31, 2024 | $1.77B | +11.9% |
| Q4 FY2023 | Dec 31, 2023 | $2.42B | +36.4% |
| Q3 FY2023 | Sep 30, 2023 | $1.85B | +10.9% |
| Q2 FY2023 | Jun 30, 2023 | $1.80B | +0.1% |
| Q1 FY2023 | Mar 31, 2023 | $1.58B | -9.1% |
| Q4 FY2022 | Dec 31, 2022 | $1.77B | -13.7% |
| Q3 FY2022 | Sep 30, 2022 | $1.67B | -7.0% |
| Q2 FY2022 | Jun 30, 2022 | $1.79B | -4.2% |
| Q1 FY2022 | Mar 31, 2022 | $1.74B | -7.3% |
| Q4 FY2021 | Dec 31, 2021 | $2.05B | +0.1% |
| Q3 FY2021 | Sep 30, 2021 | $1.79B | -3.1% |
| Q2 FY2021 | Jun 30, 2021 | $1.87B | +6.2% |
| Q1 FY2021 | Mar 31, 2021 | $1.88B | -9.0% |
| Q4 FY2020 | Dec 31, 2020 | $2.05B | +4.6% |
| Q3 FY2020 | Sep 30, 2020 | $1.85B | +1.2% |
| Q2 FY2020 | Jun 30, 2020 | $1.76B | -6.9% |
| Q1 FY2020 | Mar 31, 2020 | $2.06B | +11.2% |
| Q4 FY2019 | Dec 31, 2019 | $1.96B | -0.7% |
| Q3 FY2019 | Sep 30, 2019 | $1.83B | -7.4% |
| Q2 FY2019 | Jun 30, 2019 | $1.89B | -6.9% |
| Q1 FY2019 | Mar 31, 2019 | $1.86B | -19.8% |
| Q4 FY2018 | Dec 31, 2018 | $1.97B | -19.4% |
| Q3 FY2018 | Sep 30, 2018 | $1.98B | -23.9% |
| Q2 FY2018 | Jun 30, 2018 | $2.03B | -27.4% |
| Q1 FY2018 | Mar 31, 2018 | $2.32B | -16.4% |
| Q4 FY2017 | Dec 31, 2017 | $2.44B | -27.9% |
| Q3 FY2017 | Sep 30, 2017 | $2.60B | -7.2% |
| Q2 FY2017 | Jun 30, 2017 | $2.80B | – |
| Q1 FY2017 | Mar 31, 2017 | $2.77B | – |
| Q4 FY2016 | Dec 31, 2016 | $3.39B | – |
| Q3 FY2016 | Sep 30, 2016 | $2.80B | – |
See a number that looks wrong?